Skip to main content

Table 4 Tumor response at 6 months in the two treatment groups in patients with and without PVTT

From: The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma

Tumor response No PVTT P PVTT types I, II, III and IV P
Sorafenib group
(n = 19)
TACE + sorafenib group
(n = 24)
Sorafenib group
(n = 21)
TACE + sorafenib group
(n = 24)
CR, n (%) 2 (10.53%) 3 (12.5%) 1.000 0 (0%) 0 (0%) -
PR, n (%) 2 (10.53%) 2 (8.33%) 1.000 1 (4.76%) 4 (16.67%) 0.352
SD, n (%) 10 (52.63%) 8 (33.33%) 0.203 8 (38.1%) 10 (41.67%) 0.807
PD, n (%) 5 (26.32%) 11 (45.83%) 0.189 12 (57.14%) 10 (41.67%) 0.300
OR, n (%) 4 (21.06%) 5 (20.83%) 1.000 1 (4.76%) 4 (16.67%) 0.352
  1. CR complete response, OR overall response (CR + PR), PD progressive disease, PR partial response, SD stable disease